- Home
- RLMD
as 11-21-2024 12:40pm EST
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 110.6M | IPO Year: | N/A |
| Target Price: | $7.50 | AVG Volume (30 days): | 120.0K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.88 - $7.22 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Relmada Therapeutics Inc. (RLMD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kelly Paul Edward | RLMD | Director | Sep 9 '24 | Buy | $2.59 | 25,000 | $64,750.00 | 212,295 | |
| CASAMENTO CHARLES J | RLMD | Director | Sep 9 '24 | Buy | $2.56 | 13,000 | $33,280.00 | 13,000 | |
| TRAVERSA SERGIO | RLMD | Chief Executive Officer | Sep 9 '24 | Buy | $2.82 | 140,000 | $395,114.52 | 384,024 | |
| Shenouda Maged | RLMD | Chief Financial Officer | Sep 9 '24 | Buy | $2.74 | 53,432 | $149,700.84 | 64,215 |
Latest Relmada Therapeutics Inc. News
RLMD Breaking Stock News: Dive into RLMD Ticker-Specific Updates for Smart Investing
Argus Research
7 hours ago
Daily – Vickers Top Insider Picks for 11/21/2024
Argus Research
a day ago
Daily – Vickers Top Insider Picks for 11/20/2024
GlobeNewswire
2 days ago
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
Argus Research
2 days ago
Daily – Vickers Top Insider Picks for 11/19/2024
Argus Research
3 days ago
Daily – Vickers Top Insider Picks for 11/18/2024
Argus Research
6 days ago
Daily – Vickers Top Insider Picks for 11/15/2024
GlobeNewswire
7 days ago
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
Argus Research
7 days ago
Daily – Vickers Top Insider Picks for 11/14/2024
Compare RLMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLMD Relmada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.